MedTrace Logo

Study of Salirasib to Treat Non-Small Cell Lung Cancer

NCT00531401 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2011-06-09

No results posted yet for this study

Summary

The purpose of this study is to determine whether Salirasib is effective to shrink or prevent the growth of the tumors associated with non-small cell lung cancer in both patients who are newly diagnosed or have recurrent disease.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Salirasib

600mg BID until disease progression or unacceptable toxicity occurs.

Sponsors & Collaborators

  • Concordia Pharmaceuticals, Inc

    lead INDUSTRY

Principal Investigators

  • Gregory J Riely, MD PhD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2009-11-30
Completion
2009-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00531401 on ClinicalTrials.gov